RhumbLine Advisers’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $853K | Buy |
22,209
+3,806
| +21% | +$146K | ﹤0.01% | 2322 |
|
|
2025
Q1 | $713K | Buy |
18,403
+386
| +2% | +$15K | ﹤0.01% | 2344 |
|
|
2024
Q4 | $609K | Sell |
18,017
-70
| -0.4% | -$2.37K | ﹤0.01% | 2541 |
|
|
2024
Q3 | $739K | Buy |
18,087
+1,425
| +9% | +$58.3K | ﹤0.01% | 2434 |
|
|
2024
Q2 | $641K | Buy |
16,662
+151
| +0.9% | +$5.81K | ﹤0.01% | 2492 |
|
|
2024
Q1 | $708K | Buy |
16,511
+3,721
| +29% | +$160K | ﹤0.01% | 2445 |
|
|
2023
Q4 | $474K | Buy |
12,790
+1,690
| +15% | +$62.6K | ﹤0.01% | 2685 |
|
|
2023
Q3 | $402K | Buy |
11,100
+555
| +5% | +$20.1K | ﹤0.01% | 2739 |
|
|
2023
Q2 | $376K | Buy |
+10,545
| New | +$376K | ﹤0.01% | 2875 |
|
|
2016
Q3 | – | Sell |
-21,480
| Closed | -$1.16M | – | 2902 |
|
|
2016
Q2 | $1.16M | Hold |
21,480
| – | – | ﹤0.01% | 1690 |
|
|
2016
Q1 | $1.09M | Buy |
21,480
+240
| +1% | +$12.2K | ﹤0.01% | 1735 |
|
|
2015
Q4 | $1.07M | Buy |
21,240
+1,040
| +5% | +$52.4K | ﹤0.01% | 1759 |
|
|
2015
Q3 | $971K | Hold |
20,200
| – | – | ﹤0.01% | 1783 |
|
|
2015
Q2 | $1.05M | Sell |
20,200
-5,520
| -21% | -$287K | ﹤0.01% | 1829 |
|
|
2015
Q1 | $1.48M | Sell |
25,720
-1,840
| -7% | -$106K | ﹤0.01% | 1604 |
|
|
2014
Q4 | $1.47M | Hold |
27,560
| – | – | ﹤0.01% | 1545 |
|
|
2014
Q3 | $1.58M | Sell |
27,560
-1,040
| -4% | -$59.8K | ﹤0.01% | 1481 |
|
|
2014
Q2 | $1.91M | Buy |
28,600
+1,120
| +4% | +$74.9K | 0.01% | 1403 |
|
|
2014
Q1 | $1.84M | Sell |
27,480
-160
| -0.6% | -$10.7K | 0.01% | 1402 |
|
|
2013
Q4 | $1.85M | Buy |
27,640
+8,240
| +42% | +$550K | 0.01% | 1421 |
|
|
2013
Q3 | $1.22M | Buy |
19,400
+10,320
| +114% | +$647K | ﹤0.01% | 1649 |
|
|
2013
Q2 | $567K | Buy |
+9,080
| New | +$567K | ﹤0.01% | 2164 |
|